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ABSTRACT
The membrane bound glycoprotein mesothelin (MSLN) is a highly specific tumor 
marker, which is currently exploited as target for drugs. There are only limited 
data available on MSLN expression by human tumors. Therefore we determined 
overexpression of MSLN across different tumor types with Functional Genomic mRNA 
(FGM) profiling of a large cancer database. Results were compared with data in articles 
reporting immunohistochemical (IHC) MSLN tumor expression. FGM profiling is a 
technique that allows prediction of biologically relevant overexpression of proteins 
from a robust data set of mRNA microarrays. This technique was used in a database 
comprising 19,746 tumors to identify for 41 tumor types the percentage of samples 
with an overexpression of MSLN compared to a normal background. A literature search 
was performed to compare the FGM profiling data with studies reporting IHC MSLN 
tumor expression. FGM profiling showed MSLN overexpression in gastrointestinal 
(12–36%) and gynecological tumors (20–66%), non-small cell lung cancer (21%) 
and synovial sarcomas (30%). The overexpression found in thyroid cancers (5%) 
and renal cell cancers (10%) was not yet reported with IHC analyses. We observed 
that MSLN amplification rate within esophageal cancer depends on the histotype 
(31% for adenocarcinomas versus 3% for squamous-cell carcinomas). Subset analysis 
in breast cancer showed MSLN amplification rates of 28% in triple-negative breast 
cancer (TNBC) and 33% in basal-like breast cancer. Further subtype analysis of TNBCs 
showed the highest amplification rate (42%) in the basal-like 1 subtype and the 
lowest amplification rate (9%) in the luminal androgen receptor subtype.
INTRODUCTION
Mesothelin (MSLN) is a membrane bound 
glycoprotein with only limited expression in normal 
tissues such as mesothelial cells lining pleural, pericardial 
and peritoneal surfaces [1]. This makes it an interesting 
target for anticancer drugs. Its function is largely unknown. 
In mice inactivation of the MSLN gene produced 
physiologically normal, fertile offspring without any 
anatomical or histological abnormalities. This demonstrated 
no essential role for MSLN for growth in mice [2]. Studies 
with immunohistochemical (IHC) analyses showed high 
MSLN expression in 100% of the epithelial mesotheliomas, 
90–100% of pancreatic and 66–100% of ovarian cancers. 
This is of interest as these tumors largely lack targets for 
targeted agents. MSLN is also known to be overexpressed 
to a lesser extent in multiple other human cancers such as 
endometrial, lung, stomach, triple negative breast, cervical, 
non-small cell lung cancer (NSCLC) and head and neck 
cancers (HNSCC) [3–8].
Increasing insight in tumor biology has accelerated 
the development of molecularly targeted drugs. Many of 
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these drugs target molecular drivers of tumor growth with 
the goal to inhibit their downstream effects in a tumor cell. 
In contrast, novel drugs are becoming available that target 
over-expressed tumor specific antigens such as MSLN 
that have no clear role in tumor genesis. Among these 
novel drugs are the antibody-drug conjugates (ADCs), 
which combine the specific targeting of an antibody with 
the potency of cytotoxins that would alone cause severe 
dose-limiting toxicities [9–11]. Critical for ADC efficacy 
is overexpression of a target antigen at the cell membrane 
of tumor cells. After internalization the toxic load is 
activated.
The same mechanism of action is exploited by 
immunotoxins, which consist of a targeting antibody 
(fragment) fused with a toxin. An interesting example 
targeting MSLN is the immunotoxin SS1P, comprising a 
portion of a Pseudomonas exotoxin [12].
Another strategy targeting tumor cells 
overexpressing a certain antigen is immunotherapy. 
An example are the cancer vaccines such as GVAX, a 
combination of two irradiated, granulocyte-macrophage 
colony stimulating factor secreting allogeneic pancreatic 
cancer cell lines which were administered to patients 
with irresectable or metastasized pancreatic cancer. 
The cancer cell lines were combined with recombinant 
live-attenuated, double-deleted Listeria monocytogenes, 
engineered to secrete MSLN into the cytosol of infected 
antigen presentation cells. The combination of these two 
agents induces an in vivo immune response to mesothelin 
expressing pancreatic cancer cells [13].
Additionally, chimeric antigen receptor 
(CAR)-engineered T cells using MSLN as a target are 
developed as adoptive T cell immunotherapy in patients 
[14]. Three clinical trials are ongoing (NCT01355965, 
NCT01583686, NCT02159716) and two partial responses 
(PR) were already reported; one in a patient with 
pancreatic cancer and one patient with malignant pleural 
mesothelioma [15].
Although several IHC studies are performed 
evaluating percentages of MSLN overexpression, these 
numbers may not reflect the actual percentages of tumors 
with useful MSLN expression as they are based on small 
numbers of tumors per type, different assays and different 
definitions of positivity.
We have recently developed a method called 
functional genomic mRNA (FGM) profiling that 
corrects gene expression data (i.e. mRNA expression 
data) for major, non-genetic, factors (e.g. physiological, 
metabolic, cell-type-specific and experimental factors) 
[16]. We observed that the residual gene expression 
signal (i.e. FGM profile) correlated strongly with somatic 
copy number alterations (SCNAs) in cancer samples. In 
other words, with FGM profiling we are capturing the 
downstream effect of SCNAs at gene expression levels. 
FGM profiling is particularly useful because of the 
public availability of microarray expression profiles for 
thousands of cancer samples. We applied this method to 
publicly available expression data of 19,746 unrelated, 
patient-derived tumor samples to gain more detailed 
information about the position of MSLN as a generalizable 
drug target in 41 tumor types and compared this data to 
currently existing IHC data from literature.
RESULTS
Mesothelin expression analyzed by FGM 
profiling
The median number of samples per tumor type 
was 161, ranging from 21 for thyroid cancer to 7,270 for 
breast cancer. The number of samples per tumor type in 
combination with the predicted percentage of samples 
with a MSLN amplification is shown in Fig. 1.
Predicted amplification of MSLN was most 
frequently found in gynecological tumors, gastrointestinal 
tumors, NSCLC (21% of N = 612) and in synovial 
sarcoma (30% of N = 34). In ovarian cancer 66% of 1,255 
tumors had a predicted MSLN amplification and in cervical 
cancers (N = 114) this was 20%. Highest predicted MSLN 
amplification rate for gastrointestinal cancer was seen in 
pancreatic adenocarcinomas (36% of N = 121), followed 
by gastric cancers (24% of N = 212) and colorectal cancers 
(21% of N = 1,131). A predicted MSLN amplification 
rate of 13% was seen for esophageal cancer (N = 185), 
which was mainly driven by the subset of esophageal 
adenocarcinomas with an MSLN amplification rate 
of 31% (N = 64). In contrast, for esophageal squamous-
cell carcinomas only a MSLN amplification rate of 3% 
(N = 109) was observed.
Additionally, predicted MSLN amplifications 
were found in 9% of the renal cell carcinomas (N = 428 
tumors), 5% of the thyroid cancers (N = 21 tumors), 5% of 
acute myeloid leukemias (N = 761 tumors) and 4% of the 
HNSCC (N = 356 tumors).
We observed a predicted MSLN amplification rate of 
10% in the total set of breast cancer samples (N = 7,270). 
Within the subset of estrogen receptor (ER) positive 
(N = 4,906) and within the subset of human epidermal 
growth factor 2 (HER2) positive (N = 1,580) breast cancer 
samples the MSLN amplification rate was 3% and 7%, 
respectively (Table 1). The observed MSLN amplification 
rate within the subset of TNBC samples (N = 1,555) 
was 28%. Within the subset of breast cancer samples 
for which we were informed on the molecular subtype 
classification, we observed a high MSLN amplification 
rate within the basal-like subtype (33% of N = 378). After 
applying the TNBC sub-classification according to Lehman 
et al. on the subset of TNBC samples we observed the 
highest MSLN amplification rate (42%) within the basal-like 
1 class (N = 282). The lowest amplification rate (9%) was 
observed for the luminal androgen receptor class (N = 164).
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Mesothelin expression measured 
immunohistochemically in published papers
We identified 14 published papers in which IHC 
staining for MSLN was described for a total of 2,846 
tumor samples [1, 5–8, 17–26]. The number of samples 
analyzed per tumor type ranged from 3 (gastrointestinal 
stromal tumors) to 1,209 samples (NSCLC) with a median 
of 20 per tumor type. IHC was performed with a total of 
5 different anti-MSLN staining antibodies and 13 different 
scoring systems. The most frequently used antibody 
(9 out of the 15 studies) is the 5B2 monoclonal antibody 
from Novocastra [5, 18–21, 24, 25, 27]. Other staining 
antibodies were K1,5B2 from Thermo-scientific, 5B2 from 
Vector Laboratories, 22A31 and K1 [1, 7, 8, 22, 23]. For 
all 15 studies, 13 different scoring strategies were applied. 
Only the Ordonez papers [18, 19] used the same scoring 
system, and also Kachala [6] and Tozbikian [8] used the 
same method.
The most MSLN over-expressing tumor types were 
synovial sarcoma (100%) ovarian (50–88%), NSCLC, 
endometrioid uterine adenocarcinoma (59–64%), cervical 
(25%), pancreatic (86–100%), colorectal (28–50%), 
esophageal (25–46%) and gastric carcinoma (27–58%) 
[5, 15, 17, 18, 20–24]. Percentages of breast cancer with 
MSLN overexpression varied between studies, probably 
due to different subtypes being analyzed. In N = 43 triple 
negative breast cancer (TNBC) samples, 67% was MSLN 
positive, while in other sub types comprising 29 ER positive 
and 27 HER2 positive, this was below 5% [7]. Others 
reported a high MSLN expression in 36% of TBNC samples, 
compared to 16% in non-TNBC samples [8]. In Table 2 IHC 
MSLN expression data are shown per tumor type.
MSLN overexpression by functional genomic 
mRNA profiling versus IHC
The patterns of MSLN overexpression are largely 
comparable between the historical IHC data and our data 
gathered with FGM profiling. The percentages of tumor 
samples that showed MSLN over-expression or predicted 
MSLN amplification differ between the two techniques, 
Figure 1: MSLN overexpression calculated with FGM profiling. Values adjacent to the bars represent the absolute number of 
tumors analyzed per tumor type. The x-axis represents the predicted percentage of samples per tumor type that show an overexpression of 
MSLN. For the tumor type indicated in grey no FGM profiles were available.
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with on average higher percentages for the IHC data. 
For example, NSCLC shows in 69% of tumors an over-
expression based on IHC, while we find a predicted MSLN 
amplification rate for NSCLC of 21%. The same is true for 
the synovial sarcomas, colorectal, pancreatic and gastric 
cancers. This does not account for all tumors, as 50–88% 
of ovarian cancers are considered MSLN positive based 
on IHC, while with our technique we find 66% of ovarian 
cancer samples having a predicted MSLN amplification.
For renal cell and thyroid cancer, IHC studies were 
performed, although in small numbers of tumors (N = 33 
for renal cell, and N = 14 and N = 29 for thyroid cancer).
DISCUSSION
This is the first paper studying MSLN expression 
in a large database of human tumors with a novel method 
called FGM profiling. We showed high percentages of 
predicted MSLN amplification in gynecological tumors, 
gastrointestinal tumors, NSCLC and synovial sarcomas. In 
addition, our technique revealed not yet reported predicted 
MSLN amplifications in 10% of renal cell cancers and 5% 
of thyroid cancers. In addition, we observed that MSLN 
amplification rate within esophageal cancer depends 
on the histotype (31% for adenocarcinomas versus 3% 
for squamous-cell carcinomas). Subtype analysis in 
breast cancer showed MSLN amplification rates of 28% 
in triple-negative breast cancer (TNBC) and 33% in basal-
like breast cancer. Within the TNBCs the basal-like 1 
subtype showed the highest amplification rate (42%) 
and the luminal androgen receptor subtype the lowest 
amplification rate (9%).
This data suggests which percentages of tumor 
types potentially might benefit from treatment with MSLN 
targeting immunotoxins or ADCs. For mesothelioma, 
pancreatic and ovarian cancer, drugs are currently in 
Table 1: Predicted MSLN amplification rate in breast cancer subtypes










TNBC 1114 71.64 441 28.36 1555
non-TNBC 5459 95.52 256 4.48 5715
ER-positive 4741 96.64 165 3.36 4906
HER2-positive 1472 93.16 108 6.84 1580










Normal-like 118 98.33 2 1.67 120
Luminal A 326 99.69 1 0.31 327
Luminal B 154 94.48 9 5.52 163
Her2 118 93.65 8 6.35 126
Basal 254 67.20 124 32.80 378










Basal-like 1 164 58.16 118 41.84 282
Basal-like 2 98 76.56 30 23.44 128
Mesenchymal 156 63.41 90 36.59 246
Mesenchymal  
stem–like 130 87.84 18 12.16 148
Immunomodulatory 226 71.97 88 28.03 314
Luminal androgen 
receptor 150 91.46 14 8.54 164
*1Molecular sub-classification according to methods: Hu et al. - Parker et al. - Sorlie et al. [30–32]
*2TNBC subclassification according to Lehmann et al. [33]
Oncotarget28168www.impactjournals.com/oncotarget
Table 2: Individual MSLN immunohistochemistry studies published
Tumor type % positive N* Reference£
Non-small cell lung carcinoma
Non-small cell lung carcinoma
Non-small cell lung carcinoma





















Melanoma 0% 6 18
Primitive neuroectodermal tumor 0% 6 18































































































































Ewing’s sarcoma 0% 6 18
Synovial sarcoma 100% 9 18
(Continued )
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development that target MSLN [3, 12, 15, 28, 29]. 
However, also for the lower percentages of MSLN 
over-expressing tumors within other tumor types over-
expression of MSLN could be an interesting target. In 
this era of individualized treatment, tumor histology types 
alone do not have to determine which therapy will be 
most effective. Increasingly, drug development focuses on 
tumor characteristics and targeting these, than on tumor 
type alone.
IHC is most often applied for a semi-quantitative 
analysis of protein expression in tumor samples. However, 
IHC studies have well-known disadvantages, the first 
being highly heterogeneous scoring methods between 
different studies. For example, Frierson et al. classified 
MSLN protein expression as 1+ when only 1–10% of 
tumor cells showed positive staining, while others use 
a combination of staining intensity and percentage of 
positive stained tumor cells [5–8, 18, 20–26]. Moreover, 
different staining antibodies have been used in the 
different studies. This makes it currently difficult to 
compare IHC patterns in different studies of different 
tumor types. Also it precludes a general cut off for IHC 
indicating over-expression of MSLN. If a relevant target, 
standardization of IHC for MSLN would be clearly 
required. FGM profiling provides a rapid screening tool 
for potentially drugable targets in a large set of tumors, 
but also has some drawbacks. No quantitative analysis 
is possible and there is no direct correlation between the 
FGM profile and protein levels of the genes investigated. 
Moreover, it is not possible determine heterogeneity in 
expression between tumor cells or to determine which cell 
type in the tumor tissue expresses MSLN.
The advantages of FGM profiling however prevail 
and include that predicted MSLN amplification rates 
between tumor types are directly comparable as the same 
threshold is used. In addition, the large number of samples 
included in this analysis and the broad spectrum of tumor 
types allow for robust estimations of predicted MSLN 
amplification rates. FGM profiling may also be useful in 
determining over-expression of other potentially drugable 
targets in different tumor types. This highly facilitates 
prioritization of tumor types for future research in which 
the clinical benefit of targeting MSLN with immunotoxins 
or ADCs.
MATERIALS AND METHODS
Functional genomic mRNA profiling
For a detailed description of FGM profiling we refer 
to Fehrmann et al. [16]. In short, we analyzed 77,840 
expression profiles of publicly available samples with 
principal component analysis (PCA) and found that a 
limited number of ‘Transcriptional Components’ (TCs) 
capture the major regulators of the mRNA transcriptome. 
Subsequently, we identified a subset of TCs that described 
non-genetic regulatory factors. We used these non-genetic 
TCs as covariates to correct microarray expression data 
and observed that the residual expression signal (i.e. FGM 
profile) captures the downstream consequences of genomic 
alterations on gene expression levels.
Identification of 19,746 unrelated, 
patient-derived tumor samples
As described in more detail in Fehrmann et al, we 
were able to construct a set of 15,878 unrelated tumor 
samples of patients. In short, each of the 77,840 samples 
was annotated with MeSH terms based on an automatic 
text-mining algorithm. Next, we developed a method to 
Tumor type % positive N* Reference£
Leiomyosarcoma 0% 5 18
Gastrointestinal stromal tumor 0% 3 18
B-cell lymphoma 0% 8 18
T-cell lymphoma 0% 8 18





















Head and Neck cancer 67% 6 1
*N is the number of tumor samples analyzed in the study.£Percentage positive is the percentage of all tumors analyzed 
(in column N) that were mesothelin positive, according to the original article.
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exclude cell line samples, as these samples might not 
reflect the in vivo situation of cancer cells. Subsequently, 
we developed a method that can accurately detect and 
exclude genetically identical samples in expression data, 
even if two different cell types or tissues had been assayed 
for one individual. In addition, we performed a manual 
curation to assign each sample to one of 41 tumor types. 
Next to these 15,878 tumor samples, we identified an 
additional 3,545 breast cancer samples, 114 esophageal 
cancer samples, 30 pancreas cancers and 179 HNSCCs. 
For the breast cancer samples data on hormone receptor 
(ER, PR) and HER2 status was collected including 
the cut-off values used to define a positive or negative 
receptor status. We used this information to determine 
the receptor status of ER, PR and HER2 according to the 
latest guidelines as defined by the American Society of 
Clinical Oncology [30]. In accordance with this guideline, 
for ER and PR status, we used an IHC cut-off value of 1%. 
Samples were considered to be HER2-positive when they 
reached an IHC score of 3+. In addition, samples with a 
HER2 IHC score of 2+ with a HER2/CEP17 ratio ≥ 2.0 
were also considered positive. A HER2 IHC score of +1 
or 0 was considered negative. If we could not redefine 
the receptor status according to the ASCO guidelines, we 
explored the empirical expression distributions (regular 
mRNA expression and FGmRNA expression) for ER, PR 
and HER2 receptor status of negative and positive breast 
cancer samples (receptor status defined according to 
guidelines). Both ER and PR positive and negative status 
was best discriminated by the regular mRNA expression 
levels of the Affymetrix probe 205255_at. HER2 positive 
and negative receptor status was best discriminated by 
the FGmRNA expression level of Affymetrix probe 
216836_s_at. We used these probes to infer receptor 
status of samples that were missing ER, PR or HER2 
status according to guidelines. Thresholds were defined 
by selecting the (FG)mRNA expression value that resulted 
in the optimal balance in sensitivity between the reported 
guideline negative and positive samples. In addition, 
we collected all available molecular sub-classifications 
(normal-like, basal, luminal A, luminal B and Her2) 
for the breast cancer samples [30–32]. For the TBNC 
samples we determined the sub-classification according to 
Lehmann et al. (basal-like 1, basal-like 2, mesenchymal, 
mesenchymal stem-like, immunomodulatory and luminal 
androgen receptor) [33].
Finally, we applied FGM profiling to determine the 
FGM-landscape in these 19,746 tumor samples.
Predicting MSLN amplification rates
For MSLN we quantified the percentage of samples 
across 41 tumor types with a significantly increased FGM-
signal (i.e. proxy for underlying gene amplification). The 
threshold (except for breast cancer, pancreas cancer, 
esophageal cancer and HNSCC) was defined in 18,713 
FGM-profiles of non-cancer samples by calculating the 
97.5th percentiles for the FGM signal of MSLN. For breast 
cancer, pancreas cancer, esophageal cancer and HNSCC 
we used tissue type matched healthy samples (172, 77, 47 
and 277 samples, respectively) to determine the 97.5th 
percentiles for the FGM signal of MSLN.
For each of the 19,746 tumor samples, MSLN was 
marked as significantly amplified when the FGM-signal 
was above the 97.5th percentile threshold as defined in the 
non-cancer samples.
Literature search
To compare the data obtained with FGM profiling 
with IHC data in literature, PubMed was searched for 
articles published in English during the period 1996 until 
January 2015. The following search terms were used: 
‘mesothelin’, ‘expression’, ‘cancer’ and ‘tumor’ in various 
combinations. The articles that were found were screened 
for presence of IHC staining’s of patient derived tumor 
tissue. Subsequently, numbers of tumor samples assessed 
and percentages of tumor samples that were called MSLN 
“positive” by IHC were recorded per tumor type per 
article. MSLN positivity was decided to be present when 
it was determined as positive in the original article.
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